Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A HULL

Allopathic & Osteopathic Physicians Dermatology

NPI
1124081849
CMS profile
142103
Location
ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$676.63

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A HULL

NPI 1124081849 · CMS profile ID 142103

Allopathic & Osteopathic Physicians / Dermatology

ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $676.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $4.3112/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080155 CMS
ABBVIE INC. $118.0011/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202080153 CMS
Novartis Pharmaceuticals Corporation $17.6711/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200245362 CMS
GENZYME CORPORATION $13.6710/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233384783 CMS
REVANCE THERAPEUTICS, INC. $25.0010/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251165493 CMS
ABBVIE INC. $42.5010/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202080151 CMS
ABBVIE INC. $2.4810/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080149 CMS
Galderma Laboratories, L.P. $14.1309/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656628 CMS
ABBVIE INC. $28.9009/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202080147 CMS
ABBVIE INC. $9.7008/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080145 CMS
ABBVIE INC. $9.9208/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080143 CMS
Novartis Pharmaceuticals Corporation $19.2806/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208625 CMS
ABBVIE INC. $18.8106/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080141 CMS
Galderma Laboratories, L.P. $5.8906/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656626 CMS
ABBVIE INC. $10.2906/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080139 CMS
Lilly USA, LLC $121.2006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186550888 CMS
Galderma Laboratories, L.P. $14.0005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656624 CMS
Arcutis Biotherapeutics, Inc. $24.2904/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252333466 CMS
ABBVIE INC. $7.5704/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080137 CMS
Lilly USA, LLC $18.7403/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186499763 CMS
Novartis Pharmaceuticals Corporation $16.5602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208611 CMS
Galderma Laboratories, L.P. $133.7201/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656622 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,430.05 27
PY2020 $231.11 11
PY2021 $627.01 26
PY2022 $517.89 25
PY2023 $1,474.67 21
PY2024 $880.69 32
PY2025 $676.63 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,038.55 259
PY2024 Principal investigator $408,860.46 382
PY2023 Principal investigator $228,849.11 170
PY2022 Recipient $321.00 1
PY2022 Principal investigator $248,165.36 66
PY2021 Recipient $2,700.00 2
PY2021 Principal investigator $244,500.15 37
PY2020 Recipient $643.47 2
PY2020 Principal investigator $251,307.20 46
PY2019 Recipient $4.75 1
PY2019 Principal investigator $990,287.65 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

170 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $240.00 12/31/2023 Non-covered Recipient Entity
NW AR CLINICAL TRIALS CENTER
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 998415813
Principal investigator 1 Eli Lilly and Company $7,000.00 12/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A PHASE 2B DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1038117675
Principal investigator 1 Incyte Corporation $1,372.90 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750015
Principal investigator 1 Incyte Corporation $33.00 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750029
Principal investigator 1 Incyte Corporation $32.00 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750047
Principal investigator 1 Incyte Corporation $32.00 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750543
Principal investigator 1 Incyte Corporation $32.00 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750559
Principal investigator 1 Incyte Corporation $33.00 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750575
Principal investigator 1 Incyte Corporation $32.00 12/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750591
Principal investigator 1 Incyte Corporation $1,342.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749959
Principal investigator 1 Incyte Corporation $1,430.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749969
Principal investigator 1 Incyte Corporation $1,469.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749983
Principal investigator 1 Incyte Corporation $1,481.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749999
Principal investigator 1 Incyte Corporation $1,875.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750061
Principal investigator 1 Incyte Corporation $1,942.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750077
Principal investigator 1 Incyte Corporation $570.80 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750085
Principal investigator 1 Incyte Corporation $1,342.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750495
Principal investigator 1 Incyte Corporation $1,430.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750509
Principal investigator 1 Incyte Corporation $1,430.00 12/04/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750525
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,500.00 11/21/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053792351
Principal investigator 1 Incyte Corporation $1,696.20 11/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749931
Principal investigator 1 Incyte Corporation $1,515.00 11/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749943
Principal investigator 1 Incyte Corporation $2,499.00 11/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750463
Principal investigator 1 Incyte Corporation $1,515.00 11/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750475
Principal investigator 1 Incyte Corporation $312.70 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749853
Principal investigator 1 Incyte Corporation $2,128.00 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749869
Principal investigator 1 Incyte Corporation $1,596.00 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749885
Principal investigator 1 Incyte Corporation $1,430.00 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749901
Principal investigator 1 Incyte Corporation $1,875.00 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749917
Principal investigator 1 Incyte Corporation $1,469.00 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750429
Principal investigator 1 Incyte Corporation $1,596.00 11/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750447
Principal investigator 1 Incyte Corporation $33.54 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750117
Principal investigator 1 Incyte Corporation $23.74 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750133
Principal investigator 1 Incyte Corporation $63.96 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750149
Principal investigator 1 Incyte Corporation $47.48 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750165
Principal investigator 1 Incyte Corporation $67.08 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750179
Principal investigator 1 Incyte Corporation $159.90 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750193
Principal investigator 1 Incyte Corporation $13.86 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750207
Principal investigator 1 Incyte Corporation $30.50 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750239
Principal investigator 1 Incyte Corporation $114.50 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750253
Principal investigator 1 Incyte Corporation $67.08 11/02/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750607
Principal investigator 1 Incyte Corporation $1,077.50 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749805
Principal investigator 1 Incyte Corporation $1,724.00 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749821
Principal investigator 1 Incyte Corporation $1,635.00 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749837
Principal investigator 1 Incyte Corporation $2,499.00 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750365
Principal investigator 1 Incyte Corporation $2,499.00 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750381
Principal investigator 1 Incyte Corporation $1,724.00 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750397
Principal investigator 1 Incyte Corporation $1,635.00 10/23/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750413
Principal investigator 1 Incyte Corporation $7,000.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749677
Principal investigator 1 Incyte Corporation $500.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749695
Principal investigator 1 Incyte Corporation $67.40 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749711
Principal investigator 1 Incyte Corporation $2,128.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749727
Principal investigator 1 Incyte Corporation $1,469.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749743
Principal investigator 1 Incyte Corporation $1,430.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749759
Principal investigator 1 Incyte Corporation $1,342.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749777
Principal investigator 1 Incyte Corporation $1,875.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040749793
Principal investigator 1 Incyte Corporation $2,161.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750267
Principal investigator 1 Incyte Corporation $2,128.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750285
Principal investigator 1 Incyte Corporation $1,342.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750301
Principal investigator 1 Incyte Corporation $2,128.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750317
Principal investigator 1 Incyte Corporation $1,430.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750329
Principal investigator 1 Incyte Corporation $1,342.00 10/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040750347
Principal investigator 1 Incyte Corporation $22.29 10/03/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750101
Principal investigator 1 Incyte Corporation $120.02 10/03/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040750223
Principal investigator 1 Incyte Corporation $7,000.00 09/25/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748909
Principal investigator 1 Incyte Corporation $500.00 09/25/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748925
Principal investigator 1 Journey Medical Corporation $16,150.00 09/21/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
DFD-29-CD-004 No dispute reported 06/30/2026 1054448737
Principal investigator 1 Novartis Pharmaceuticals Corporation $85.39 09/11/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CENTER FOR PLASTIC SURGERY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1017196545
Principal investigator 1 Incyte Corporation $5,446.80 09/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748891
Principal investigator 1 Incyte Corporation $60.84 09/01/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749579
Principal investigator 1 Incyte Corporation $721.60 09/01/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749597
Principal investigator 1 Incyte Corporation $43.98 09/01/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749613
Principal investigator 1 Incyte Corporation $304.06 09/01/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749629
Principal investigator 1 ABBVIE INC. $7,650.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396173
Principal investigator 1 ABBVIE INC. $351.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396175
Principal investigator 1 ABBVIE INC. $248.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396183
Principal investigator 1 ABBVIE INC. $124.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396185
Principal investigator 1 ABBVIE INC. $434.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396187
Principal investigator 1 ABBVIE INC. $434.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396189
Principal investigator 1 ABBVIE INC. $186.00 08/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998396191
Principal investigator 1 ABBVIE INC. $2,300.00 08/15/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 998395617
Principal investigator 1 ABBVIE INC. $8,133.00 08/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 998394291
Principal investigator 1 Incyte Corporation $11,853.90 08/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748875
Principal investigator 1 Incyte Corporation $9,988.20 07/12/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748941
Principal investigator 1 Incyte Corporation $47.48 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748957
Principal investigator 1 Incyte Corporation $67.08 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748973
Principal investigator 1 Incyte Corporation $33.54 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748989
Principal investigator 1 Incyte Corporation $63.96 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749007
Principal investigator 1 Incyte Corporation $59.35 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749021
Principal investigator 1 Incyte Corporation $3.24 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749037
Principal investigator 1 Incyte Corporation $42.25 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749053
Principal investigator 1 Incyte Corporation $43.28 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749073
Principal investigator 1 Incyte Corporation $6.10 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749089
Principal investigator 1 Incyte Corporation $6.80 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749105
Principal investigator 1 Incyte Corporation $22.29 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749121
Principal investigator 1 Incyte Corporation $22.20 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749499
Principal investigator 1 Incyte Corporation $127.08 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749515
Principal investigator 1 Incyte Corporation $22.90 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749531
Principal investigator 1 Incyte Corporation $24.34 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749549
Principal investigator 1 Incyte Corporation $76.84 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749565
Principal investigator 1 Incyte Corporation $67.08 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749645
Principal investigator 1 Incyte Corporation $47.48 07/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040749661
Principal investigator 1 ABBVIE INC. $532.80 06/08/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998386181
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,487.52 06/07/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, Llc
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1027488553
Principal investigator 1 Incyte Corporation $29.90 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748479
Principal investigator 1 Incyte Corporation $60.00 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748497
Principal investigator 1 Incyte Corporation $60.00 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748513
Principal investigator 1 Incyte Corporation $11.79 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748561
Principal investigator 1 Incyte Corporation $11.79 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748641
Principal investigator 1 Incyte Corporation $17.61 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748673
Principal investigator 1 Incyte Corporation $29.90 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748811
Principal investigator 1 Incyte Corporation $60.00 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748827
Principal investigator 1 Incyte Corporation $60.00 04/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748841
Principal investigator 1 Incyte Corporation $29.90 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748413
Principal investigator 1 Incyte Corporation $60.00 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748433
Principal investigator 1 Incyte Corporation $60.00 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748447
Principal investigator 1 Incyte Corporation $139.56 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748463
Principal investigator 1 Incyte Corporation $627.76 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748529
Principal investigator 1 Incyte Corporation $29.90 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748689
Principal investigator 1 Incyte Corporation $29.90 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748727
Principal investigator 1 Incyte Corporation $29.90 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748745
Principal investigator 1 Incyte Corporation $60.00 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748761
Principal investigator 1 Incyte Corporation $60.00 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748777
Principal investigator 1 Incyte Corporation $139.56 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748793
Principal investigator 1 Incyte Corporation $627.76 04/21/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748859
Principal investigator 1 Incyte Corporation $762.90 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748365
Principal investigator 1 Incyte Corporation $94.61 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748383
Principal investigator 1 Incyte Corporation $139.56 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748399
Principal investigator 1 Incyte Corporation $35.00 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748545
Principal investigator 1 Incyte Corporation $13.95 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748577
Principal investigator 1 Incyte Corporation $687.90 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748593
Principal investigator 1 Incyte Corporation $13.90 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748609
Principal investigator 1 Incyte Corporation $23.12 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748625
Principal investigator 1 Incyte Corporation $17.61 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748657
Principal investigator 1 Incyte Corporation $94.61 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748707
Principal investigator 1 Incyte Corporation $139.56 04/20/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040748715
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $7,222.40 04/05/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128533
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,500.00 03/22/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) No dispute reported 06/30/2026 1025128445
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,500.00 03/21/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) No dispute reported 06/30/2026 1053792361
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,000.00 03/21/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) No dispute reported 06/30/2026 1053792371
Principal investigator 1 Eli Lilly and Company $23,051.40 03/17/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1038115117
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748015
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748031
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748047
Principal investigator 1 Incyte Corporation $49.56 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748079
Principal investigator 1 Incyte Corporation $17.42 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748113
Principal investigator 1 Incyte Corporation $30.81 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748147
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748181
Principal investigator 1 Incyte Corporation $48.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748203
Principal investigator 1 Incyte Corporation $10.42 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748221
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748237
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748284
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748299
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748315
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748331
Principal investigator 1 Incyte Corporation $623.74 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040747967
Principal investigator 1 Incyte Corporation $143.19 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040747983
Principal investigator 1 Incyte Corporation $139.99 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040747999
Principal investigator 1 Incyte Corporation $326.57 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748063
Principal investigator 1 Incyte Corporation $17.42 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748095
Principal investigator 1 Incyte Corporation $688.80 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748129
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748165
Principal investigator 1 Incyte Corporation $143.19 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748253
Principal investigator 1 Incyte Corporation $139.99 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748267
Principal investigator 1 Incyte Corporation $326.57 03/09/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040748349
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,074.60 02/28/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053792341
Principal investigator 1 ABBVIE INC. $1,340.40 02/15/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 998370733
Principal investigator 1 Novartis Pharmaceuticals Corporation $183.07 01/15/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CENTER FOR PLASTIC SURGERY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1017197075
Principal investigator 1 Eli Lilly and Company $0.99 01/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1038124317
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,623.80 01/06/2023 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER, LLC
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1017233769